Articles

The XXVII Congress of the International Society on Thrombosis and Haemostasis
News

The XXVII Congress of the International Society on Thrombosis and Haemostasis

Find us at booth #1113 in the exhibition area. We have some surprises for you in store.

Read More
Mouse models of cancer-associated thrombosis
Basic Mechanism

Mouse models of cancer-associated thrombosis

The incidence of VTE is varied with cancer type, suggesting that there may be cancer-type specific mechanisms. However, the underlying mechanisms have not been elucidated. Mouse models are used to investigate the mechanisms of cancer-associated thrombosis. Many different mouse models have been established that vary by mouse strains, cancer cells, tumor sites and thrombosis models.

Read More
Welcome LEO Pharma
News

Welcome LEO Pharma

Founded in 1908, LEO Pharma is a foundation-owned company that has devoted decades of research and development to advance the science of thrombosis, setting new standards of care, always putting the patient first.

Read More
DOACs in the treatment of cancer-associated thrombosis
Methodology

DOACs in the treatment of cancer-associated thrombosis

Since the publication of the SELECT-D trial and the Hokusai-VTE Cancer study, there has been a shift in the treatment of cancer-associated thrombosis.

Read More
Venous thromboembolism in blood or marrow transplant recipients
Epidemiology

Venous thromboembolism in blood or marrow transplant recipients

Cancer is a well-recognized risk factor for venous thromboembolism (VTE) and several risk prediction models have been developed to identify patients at high risk. However, the majority of patients included in these studies had solid tumors, and blood or marrow transplant recipients were excluded...

Read More
VIII Forum of Thrombosis Oncology
News

VIII Forum of Thrombosis Oncology

The VIII Oncology Forum on Thrombosis is going to be held in Madrid, 22-23 February 2019.

Read More
The Pediatric Issue
News

The Pediatric Issue

This special issue of ICTHIC magazine will focus upon challenging issues dealing with children with cancer and thrombosis, the potential role of thrombophilic risk factors and current and future treatments.

Read More
An update on the status of direct oral anticoagulants in children
Trial Update

An update on the status of direct oral anticoagulants in children

Until recently, paediatric investigators focused their efforts on closing the knowledge gap on how to better use classic AC in children.

Read More
The safety of DOACs to treat VTE in patients with brain tumors
Anticoagulation Drugs

The safety of DOACs to treat VTE in patients with brain tumors

Patients with primary and metastatic brain tumors have a high risk of venous thromboembolism, occurring in 20-30% depending on primary tumor type. Anticoagulant therapy for patients with brain tumors is challenging given concerns regarding risk of clinically significant intracranial hemorrhage, which occurs at a rate of between 2-20% in patients not receiving anticoagulation [3-4].

Read More
Arterial thrombosis and pediatric cancer- should cancer associated pediatric stroke be studied?
Epidemiology

Arterial thrombosis and pediatric cancer- should cancer associated pediatric stroke be studied?

While knowledge of arterial thromboembolism prevalence and risk factors among adult cancer patients is currently growing, there seems to be only scarce information regarding arterial thrombosis in general or stroke in particular, among patients and survivors of pediatric cancer.

Read More

Page 1 of 6